Evolus (NASDAQ:EOLS) Rating Lowered to “Hold” at Wall Street Zen

Evolus (NASDAQ:EOLS) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Sunday.

A number of other brokerages also recently weighed in on EOLS. Mizuho set a $15.00 price objective on shares of Evolus in a research report on Wednesday, February 4th. Stifel Nicolaus decreased their price objective on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, January 13th. Needham & Company LLC restated a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. BTIG Research reiterated a “buy” rating and set a $13.00 price target on shares of Evolus in a research report on Wednesday, March 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a report on Monday, December 22nd. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Evolus currently has an average rating of “Moderate Buy” and an average target price of $16.00.

Evolus Stock Up 2.0%

NASDAQ:EOLS opened at $5.01 on Friday. The company has a market cap of $325.95 million, a PE ratio of -6.19 and a beta of 1.02. The business’s 50 day moving average is $4.89 and its two-hundred day moving average is $6.14. Evolus has a 52 week low of $4.09 and a 52 week high of $13.66.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The firm had revenue of $90.30 million during the quarter, compared to analyst estimates of $89.58 million. As a group, sell-side analysts expect that Evolus will post -0.61 EPS for the current fiscal year.

Insider Activity at Evolus

In related news, insider David Moatazedi sold 10,539 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the sale, the insider directly owned 354,388 shares in the company, valued at $2,533,874.20. The trade was a 2.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Rice Hall James & Associates LLC boosted its stake in shares of Evolus by 17.4% during the 3rd quarter. Rice Hall James & Associates LLC now owns 1,168,886 shares of the company’s stock worth $7,177,000 after acquiring an additional 172,846 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in shares of Evolus during the second quarter worth $22,431,000. Frontier Capital Management Co. LLC raised its position in shares of Evolus by 37.9% during the second quarter. Frontier Capital Management Co. LLC now owns 1,664,828 shares of the company’s stock worth $15,333,000 after purchasing an additional 457,533 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Evolus during the second quarter valued at $434,000. Finally, Squarepoint Ops LLC lifted its holdings in shares of Evolus by 830.2% during the second quarter. Squarepoint Ops LLC now owns 105,797 shares of the company’s stock valued at $974,000 after purchasing an additional 94,423 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.